Phase 1/2 trial of acalabrutinib plus pembrolizumab (Pem) in relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

被引：0

作者：

Witzig, Thomas E.

Maddocks, Kami J.

De Vos, Sven

Lyons, Roger M.

Edenfield, William Jeffery

Sharman, Jeff Porter

Vose, Julie

Yimer, Habte Aragaw

Wei, Helen

Chan, Edward M.

Patel, Priti

Di Simone, Christopher

Gandhi, Mitul

Vaughn, Jennifer

Kolibaba, Kathryn

Cheson, Bruce D.

Samaniego, Felipe

机构：

[1] Mayo Clin, Rochester, MN USA

[2] Ohio State Univ, Columbus, OH 43210 USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[4] Texas Oncol, San Antonio, TX USA

[5] US Oncol Res, San Antonio, TX USA

[6] Greenville Hlth Syst Canc Inst, Greenville, SC USA

[7] US Oncol, Springfield, OR USA

[8] Willamette Valley Canc Inst, Springfield, OR USA

[9] Nebraska Med Ctr, Omaha, NE USA

[10] US Oncol Res, Texas Oncol Tyler, Tyler, TX USA

[11] Acerta Pharma, San Francisco, CA USA

[12] Arizona Oncol Associates, Tucson, AZ USA

[13] US Oncol Res, Virginia Canc Specialists, Woodbridge, VA USA

[14] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[15] US Oncol Res, Northwest Canc Specialists PC, Vancouver, WA USA

[16] Georgetown Univ Hosp, Washington, DC 20007 USA

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7519

引用

页数：2

共 50 条

[1] Phase 1/2 Trial of Acalabrutinib Plus Pembrolizumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
不详
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (08) : 9 - 10
[2] Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial
de Vos, Sven
Reagan, Patrick M.
Patel, Manish R.
Saba, Nakhle S.
Mortlock, Andrew
Cerec, Virginie
Munugalavadla, Veerendra
Acar, Melih
Nuttall, Barrett
Jenkins, David
White, Rafael
Callahan, Megan
Forcina, Alessandra
Roschewski, Mark
Flinn, Ian W.
[J]. BLOOD, 2022, 140 : 6635 - 6637
[3] Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Dyer, Martin J. S.
De Vos, Sven
Ruan, Jia
Flowers, Christopher
Maddocks, Kami J.
Rule, Simon
Hamdy, Ahmed M.
Izumi, Raquel
Slatter, J. Greg
Cheung, Jean
Frigualt, Melanie M.
Wei, Helen
Mourya, Sanchita
Hunder, Naomi N. H.
Fowler, Nathan Hale
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[4] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Kalakonda, Nagesh
Cavallo, Federica
Follows, George
Goy, Andre
Vermaat, Joost S. P.
Casasnovas, Olivier
Lavee, Orly
Maerevoet, Marie
Zijlstra, Josee
Bakhshi, Sameer
Bouabdallah, Reda
Choquet, Sylvain
Gurion, Ronit
Hill, Brian
Jaeger, Ulrich
Sancho, Juan-Manuel
Schuster, Michael
Thieblemont, Catherine
De la Cruz, Fatima
Egyed, Miklos
Mishra, Sourav
Offner, Fritz
Vassilakopoulos, Theodoros
Warzocha, Krzysztof
McCarthy, Daniel
Ma, Xiwen
Corona, Kelly
Saint-Martin, Jean-Richard
Joshi, Anita
Shah, Jatin
Van den Neste, Eric
Canales, Miguel
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
[5] Total Cost of Care in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Gatwood, Justin
Masaquel, Anthony
Ross, Ryan
Sheinson, Danny
Hossain, Farah
Li, Jia
James, Cameron
Fox, David
[J]. BLOOD, 2022, 140 : 7906 - 7907
[6] Magrolimab in Combination with Rituximab plus Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Maakaron, Joseph
Asch, Adam S.
Popplewell, Leslie L.
Collins, Graham P.
Flinn, Ian W.
Ghosh, Nilanjan
Keane, Colin
Ku, Matthew
Mehta, Amitkumar
Roschewski, Mark
O'Hear, Carol
Ren, Xuehan
Villa, Bertha
Lal, Indu
Smith, Sonali M.
Advani, Ranjana H.
[J]. BLOOD, 2022, 140 : 3728 - 3730
[7] Results from a phase 1b study of blinatumomab-pembrolizumab combination in adults with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
Giri, Pratyush
Patil, Sushrut
Ratnasingam, Sumita
Prince, H. Miles
Milliken, Samuel
Meijide, Javier Briones
Coyle, Luke
Van der Poel, Marjolein
Mulroney, Carolyn M.
Farooqui, Mohammed Z. H.
Wong, Hansen
Desai, Rajendra
Zugmaier, Gerhard
Mergen, Noemi
Cannell, Paul
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[8] Understanding the patient experience in follicular lymphoma (FL), relapsed/refractory FL (R/R FL), and relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL)
Bell, Jill A.
Cherepanov, Dasha
Revicki, Dennis
Speck, Rebecca M.
Swett, Laura
Stumpo, Kate
Rong, Yuanxin
Gordon, Leo I.
[J]. QUALITY OF LIFE RESEARCH, 2019, 28 : S67 - S68
[9] Patient, Caregiver, and Physician Preferences for Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Vukcevic, Mirko
Yung, Mallory
Khan, Mali
Houpt, Bethany
Schnell, Frederick
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S376 - S377
[10] Patient, caregiver, and physician preferences for treatment of relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
Vukcevic, Mirko
Yung, Mallory
Khan, Maliha
Schnell, Frederick Mark
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18710 - E18710

← 1 2 3 4 5 →